A Brief History of Novo Nordisk as a Leader in Diabetes Care The story of Novo Nordisk dates back to the early 1920s, when August Krogh , inspired by his wife Marie Kroghs advocacy for diabetes care , collaborated with Hans Christian Hagedorn to bring insulin to Denmark
The medication mechanism involves altering digestive enzyme secretion, which could reactivate pancreatic inflammation or trigger a life-threatening recurrence
Building on this success, the team further optimized the formula, ultimately leading to the development of semaglutide, with a longer half-life, by scientists including a research team led by Mads Krogsgaard Thomsen
New technologies, such as smart pens and continuous glucose monitoring devices, enhance the administration of GLP 1 analogues, improving patient compliance and outcomes
They work synergistically to provide relief from mealtime discomfort
Designs for Health